Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study

Journal of Internal Medicine

Volumn 280, Issue 6, 2016, Pages 618-626

  Gronlund O ^a   Herweijer, E ^a   Sundstrom K ^b   Arnheim Dahlstrom L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

autoimmune diseases; cohort study; epidemiology; infectious disease; vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CELIAC DISEASE; CHILD; COHORT ANALYSIS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LOW RISK POPULATION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PSORIASIS; RISK ASSESSMENT; RISK REDUCTION; VACCINATION; AUTOIMMUNE DISEASES; PAPILLOMAVIRUS INFECTIONS; SWEDEN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; CHILD; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SWEDEN; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84979740800     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12535     Document Type: Article

References (29)

1. Feldman CH, Kim SC. Should we target patients with autoimmune diseases for human papillomavirus vaccine uptake? Expert Rev Vaccines 2014; 13: 931–4.
2. Kim SC, Glynn RJ, Giovannucci E et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis 2014; 74: 1360–7.
3. Zard E, Arnaud L, Mathian A et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmun Rev 2014; 13: 730–5.
4. Stillo M, Carrillo Santisteve P, Lopalco PL. Safety of human papillomavirus vaccines: a review. Expert Opin Drug Saf 2015; 14: 697–712.
5. Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr 2014; 168: 76–82.
6. Feldman CH, Hiraki LT, Lii H, Seeger JD, Kim SC. Human papillomavirus vaccine uptake among individuals with systemic inflammatory diseases. PLoS One 2015; 10: e0117620.
7. Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009; 33: 197–207.
8. Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 2013; 382: 819–31.
9. Mills KHG. TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 2011; 11: 807–22.
10. Wraith DC, Goldman M, Lambert P-H. Vaccination and autoimmune disease: what is the evidence? Lancet 2003; 362: 1659–66.
11. Richard-Miceli C, Criswell LA. Emerging patterns of genetic overlap across autoimmune disorders. Genome Med 2012; 4: 6.
12. Chao C, Klein NP, Velicer CM et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2011; 271: 193–203.
13. Scheller NM, Svanström H, Pasternak B et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA 2015; 313: 54.
14. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013; 347: f5906.
15. Grimaldi-Bensouda L, Guillemot D, Godeau B et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014; 275: 398–408.
16. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013; 72: 659–64.
17. Jacobson DL, Bousvaros A, Ashworth L et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1441–9.
18. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659–67.
19. Anon. WHO | International Classification of Diseases (ICD). 2013, Available at: http://apps.who.int/classifications/icd10/browse/2010/en (Accessed 29/12/13).
20. Anon. Statistiska centralbyrån. 2015, Available at: http://www.scb.se (Accesed 15/04/15).
21. Folkhälsomyndigheten. Svevac. 2015, Available at: https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/svevac/ (Accessed 15/04/15).
22. Leval A, Herweijer E, Ploner A et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 2013; 105: 469–74.
23. Wettermark B, Hammar N, Fored CM et al. The new Swedish Prescribed Drug Register – opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726–35.
24. Jacobsen SJ, Sy LS, Ackerson BK et al. An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine 2012; 30: 4585–7.
25. Slade BA, Leidel L, Vellozzi C et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA J Am Med Assoc 2009; 302: 750–7.
26. Erlewyn-Lajeunesse M, Hunt LP, Heath PT, Finn A. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Child 2012; 97: 487–90.
27. Gee J, Naleway A, Shui I et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011; 29: 8279–84.
28. Klein NP. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012; 166: 1140.
29. Anon. Causality assessment of adverse events following immunization. Wkly Epidemiol Rec 2001; 76: 85–9.